100% free download of ACLS dumps and Practice Test

We have valid and up-to-date ACLS real questions, that really work in the actual ACLS exam. This website provides the latest tips and tricks to pass ACLS exam with our dump. With the information base of ACLS questions bank, you do not have to squander your chance on perusing Advanced Cardiac Life Support - 2022 reference books, Just go through 24 hours to master our ACLS Exam Braindumps and answers and step through the exam.

Exam Code: ACLS Practice test 2022 by Killexams.com team
ACLS Advanced Cardiac Life Support - 2022

EXAM NUMBER : ACLS
EXAM NAME : Advanced Cardiac Life Support
Grading Scale:
91-100% = A
83-90% = B
75-82% = C
67-81% = D
Below 67 = F

Skill development for professional personnel practicing in critical care units, emergency departments, and paramedic ambulances. Establishes a system of protocols for management of the patient experiencing cardiac difficulties.

COURSE CONTENTS, COURSE OBJECTIVES, SYLLABUS
- Integrate knowledge of EMS systems, safety/well being of the paramedic, and medical/legal and ethical issues, which is intended to Strengthen the health of EMS personnel, patients, and the community.
- Integrate knowledge of pharmacology to formulate a treatment plan intended to mitigate emergencies and Strengthen the overall health of the patient.
- Integrate knowledge of anatomy, physiology, and pathophysiology into the assessment to develop and implement a treatment plan with the goal of assuring a patent airway, adequate mechanical ventilation and respiration for all patients.
- Integrate scene and patient assessment findings with knowledge of epidemiology and pathophysiology to form a field impression, differential diagnosis and formulate a treatment plan.
- Integrate comprehensive knowledge of causes and pathophysiology into the management of cardiac arrest and peri-arrest states.
- Integrate a comprehensive knowledge of the causes and pathophysiology into the management of shock, respiratory failure or arrest with an emphasis on early intervention to prevent arrest.
- Safely and effectively perform all psychomotor skills within the scope of the Paramedic practice.
- Integrates comprehensive knowledge of EMS systems, the safety/well-being of the paramedic, and medical/legal and ethical issues which is intended to Strengthen the health of EMS personnel, patients, and the community.
- Integrates a complex depth and comprehensive breadth of knowledge of the anatomy and physiology of all human systems.
- Integrates comprehensive anatomical and medical terminology and abbreviations into the written and oral communication with colleagues and other health care professionals.
- Integrates comprehensive knowledge of pathophysiology of major human systems.
- Integrates comprehensive knowledge of life span development.
- Applies fundamental knowledge of principles of public health and epidemiology including public health emergencies, health promotion, and illness and injury prevention.
- Integrates comprehensive knowledge of pharmacology to formulate a treatment plan intended to mitigate emergencies and Strengthen the overall health of the patient.
- Integrates complex knowledge of anatomy, physiology, and pathophysiology into the assessment to develop and implement a treatment plan with the goal of assuring a patent airway, adequate mechanical ventilation, and respiration for patients of all ages.
- Integrate scene and patient assessment findings with knowledge of pathophysiology to form a field impression. This includes development of a list of differential diagnoses through clinical reasoning to modify the assessment and formulate a treatment plan.
- Integrates assessment findings with principles of epidemiology and pathophysiology to formulate a field impression and implement a comprehensive treatment/disposition plan for a patient with a medical complaint.
- Integrates comprehensive knowledge of causes and pathophysiology into the management of the cardiac arrest and peri-arrest states.
- Integrates a comprehensive knowledge of the causes and pathophysiology into the management of shock, respiratory failure or arrest with an emphasis on early intervention to prevent arrest.
- Integrates assessment findings with principles of epidemiology and pathophysiology to formulate a field impression to implement a comprehensive treatment/disposition plan for an acutely injured patient.
- Integrates assessment findings with principles of pathophysiology and knowledge of psychosocial needs to formulate a field impression and implement a comprehensive treatment/disposition plan for patients with special needs.
- Knowledge of operational roles and responsibilities to ensure patient, public and personnel safety.
- Communicate in a culturally sensitive manner.
- Demonstrate professional behavior including but not limited to; integrity, empathy, self-motivation, appearance and personal hygiene, self confidence, communications, time-management, teamwork, diplomacy and respect, patient advocacy and the safe delivery of care.
- Safely and effectively perform all psychomotor skills within the National EMS Scope of Practice Model and state scope of practice at the Paramedic level
- Perform basic and advanced interventions as a part of a treatment plan intended to mitigate the emergency, provide symptom relief, and Strengthen the overall health of the patient and evaluate the effectiveness of interventions and modify the treatment plan accordingly.
- Report and document assessment findings and interventions. Collect and report data to be used for epidemiological and research purposes.
- Function as the team leader of a routine, single patient advanced life support emergency call.

Advanced Cardiac Life Support - 2022
Medical Advanced download
Killexams : Medical Advanced obtain - BingNews https://killexams.com/pass4sure/exam-detail/ACLS Search results Killexams : Medical Advanced obtain - BingNews https://killexams.com/pass4sure/exam-detail/ACLS https://killexams.com/exam_list/Medical Killexams : Wearable Medical Device Market is expected to reach $11.4 Billion by 2027 – An exclusive market research report by Lucintel No result found, try new keyword!Trends and Forecast for the Global Wearable Medical Device Market Trends, opportunities and forecast in the wearable medical device market to 2027 by end use (healthcare & medical and remote patient ... Mon, 08 Aug 2022 10:58:00 -0500 https://finance.dailyherald.com/dailyherald/article/abnewswire-2022-8-8-wearable-medical-device-market-is-expected-to-reach-114-billion-by-2027-an-exclusive-market-research-report-by-lucintel Killexams : Medical Clothing Market Forecast To Surge At A Robust Pace By 2029| Top Players-Cardinal Health, 3M, Smith+Nephew,Ansell

(MENAFN- EIN Presswire)

Data Bridge Market Research Logo

DBMR analyses that the Medical Clothing Market is expected to reach USD 173.24 billion and registering a CAGR of 7.9% during the forecast period of 2022 to 2029

NEW YORK, UNITED STATES, August 9, 2022 /EINPresswire.com / -- DBMR has added a new report to their increasing litany of reports titled“Medical Clothing Market Report”. The new study encompasses valuable insights using a variety of graphs, tables and figures that explores opportunities, trends and drivers surrounding the Medical Clothing industry. This Report is created to provide the market landscape and unlimited guideline about contemporary market size, share, driving factors, trends, progressive growth, and dominant players of the Medical Clothing market. The report serves overall information on the market to top manufacturers, distributors, traders, dealers. It will help them understand the product scope, market overview, market driving force, technological innovation, market risk, opportunities, and research findings.

Data Bridge Market Research analyses that the medical clothing market was valued at USD 94.29 billion in 2021 and is expected to reach USD 173.24 billion by 2029, registering a CAGR of 7.9% during the forecast period of 2022 to 2029. The disposable segment by usage segment holds the largest share in the medical clothing market. Face masks, scrubs, research coats, headgear, and shoe covers are all commonly used medical products globally.

Download the PDF trial Copy (Including FULL TOC, Graphs and Tables) of this report @

The increased prevalence of chronic diseases has resulted in an increase in the number of patients worldwide. On the other hand, patients in hospitals are at risk of developing hospital-acquired infections (HAI). According to the World Health Organization (WHO), at any given moment, 10% of hospitals in underdeveloped countries and roughly 7% of hospitals in affluent nations document at least one incidence of HAI. As a result, there has been a greater emphasis on enhancing hospital infrastructure and ensuring optimum hygiene. Hence, increasing the demand for medical clothing in the market.

The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Some of the major players operating in the Global Medical Clothing Market are:

Cardinal Health, Inc. (US)
Mölnlycke Health Care AB (Sweden)
3M (US)
Smith+Nephew (UK)
Ansell Ltd. (Australia)
Superior Group of Companies (US)
Semperit AG Holding (Austria)
Henry Schein, Inc. (US)
Narang Medical Ltd. (India)
Healing Hands (New Jersey)
BARCO UNIFORMS (US)
CHEROKEE UNIFORMS (US)
Aramark Uniform & Career Apparel (US)
Carhartt, Inc. (US)
LynkTrac Technologies LLC (US)

Scope of Report:

The Medical Clothing Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report will help you to establish a landscape of industrial development and characteristics of the Medical Clothing market. The Global Medical Clothing market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to the Regional Segmentation the Medical Clothing Market provides the Information covers following regions:

•North America
•South America
•Asia & Pacific
•Europe
•MEA (Middle East and Africa)

The key countries in each region are taken into consideration as well, such as United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Full Report is available (Including the full TOC, Tables and Figures, Graphs as well as Chart) @

This Medical Clothing Market Research/analysis Report Contains Answers to your following Questions
•Which Manufacturing Technology is used for Medical Clothing?
•What Developments Are Going On in That Technology?
•Which Trends Are Causing These Developments?
•Who Are the Global Key Players in This Medical Clothing Market?
•What are Their Company Profile, Their Product Information, and Contact Information?
•What Was Global Market Status of Medical Clothing Market?
•What Was Capacity, Production Value, Cost and PROFIT of Medical Clothing Market?
•What Is Current Market Status of Medical Clothing Industry?
•What's Market Competition in This Industry, Both Company, and Country Wise?
•What's Market Analysis of Medical Clothing Market by Taking Applications and Types in Consideration?
•What Are Projections of Global Medical Clothing Industry Considering Capacity, Production and Production Value?
•What Will Be the Estimation of Cost and Profit?
•What Will Be Market Share, Supply and Consumption?
•What about Import and Export?
•What Is Medical Clothing Market Chain Analysis by Upstream Raw Materials and Downstream Industry?
•What Is Economic Impact On Medical Clothing Industry?
•What are Global Macroeconomic Environment Analysis Results?
•What Are Global Macroeconomic Environment Development Trends?
•What Are Market Dynamics of Medical Clothing Market?
•What Are Challenges and Opportunities?
•What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Medical Clothing Industry?

Some Major TOC Points:
•Chapter 1: Medical Clothing Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.
•Chapter 2: Medical Clothing Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels, and Major Downstream Buyers.
•Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Medical Clothing.
•Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Medical Clothing.
•Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Medical Clothing by Regions.
•Chapter 6: Medical Clothing Production, Consumption, Export, and Import by Regions.
•Chapter 7: Medical Clothing Market Status and SWOT Analysis by Regions.
•Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Medical Clothing.
•Chapter 9: Medical Clothing Market Analysis and Forecast by Type and Application.
•Chapter 10: Medical Clothing Market Analysis and Forecast by Regions.
•Chapter 11: Medical Clothing Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.
•Chapter 12: Medical Clothing Market Conclusion of the Whole Report.
•Continue…

Access Full Report@

Browse More Reports From Data Bridge Market Research:

Global Cannabidiol (CBD) Oil Market, By Type (THC Dominant, CBD Dominant, Marijuana Based and Hemp Based), Product Type (Original and Blended), Product Category (Unflavoured and Flavoured), Application (Food and Beverages, Personal Care/Cosmetics, Pharma and Nutraceuticals and Industrial Application), Distribution Channel (Direct and Indirect) – Industry Trends and Forecast to 2028. :

Global Legal Marijuana Market, By Type (Recreational Marijuana, Medical Marijuana), Application (Chronic Pain, Mental Disorders, Cancer, Others), Product Type (Buds, Oils, Tinctures, Others) – Industry Trends and Forecast to 2028. :

Global Cannabidiol (CBD) Infused Edible Market – Industry Trends and Forecast to 2028:

Global Cannabidiol (CBD) Edibles Market – Industry Trends and Forecast to 2028:

Europe CBD Patch Market – Industry Trends and Forecast to 2028:

Cannabidiol (CBD) Oil Extract Market Size To Reach $ 37.74 Billion at a Thriving CAGR of 21.50% by 2029:Say DBMR Analyst:

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company.“Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Sopan Gedam
Data Bridge Market Research
+1 888-387-2818
email us here

MENAFN09082022003118003196ID1104668960


Mon, 08 Aug 2022 22:23:00 -0500 Date text/html https://menafn.com/1104668960/Medical-Clothing-Market-Forecast-To-Surge-At-A-Robust-Pace-By-2029-Top-Players-Cardinal-Health-3M-SmithNephewAnsell
Killexams : AIIMS Raipur invites applications for Advanced Diploma in Radiotherapy Technology, Pre-Hospital Trauma Technician courses, details

Raipur: All India Institute of Medical Sciences (AIIMS Raipur) has invited online applications for entrance examination for admission in Advanced Diploma in Radiotherapy Technology (ADRT) and Pre-Hospital Trauma Technician (PTT) courses - July 2022 session.

The candidates can apply till 20th August 2022. They can access the online application by clicking on the Google form link mentioned on the website www.aiimsraipur.edu.in. The application must be filled out carefully since after submission of the online application, a request for change in any information at any later stage will not be considered. While filling out the application form, the candidates should be ready with a valid email id, online payment detail of the required application fee, and an aadhar card.

Google link for the application form -

ADRT course - https://docs.google.com/forms/d/e/1FAIpQLSe03mu5NJU3s76-9vDGa4RwDx5ymLY-0L392YPJxSBUuWdaUA/viewform

PTT - https://docs.google.com/forms/d/e/1FAIpQLScec2ftaPHH8Dk8lqRxm6s-uiQ2L8qhEWpg5B1NRv2ngunESg/viewform

The candidates will have to pay the following application fee –

1. General/OBC Category - 1000/- + Transaction Charges as applicable.

2. SC/ST/EWS Category - 800/- + Transaction Charges as applicable.

3. PWBD Candidates are exempted from any Fee.

Without the payment of the application fee, the application will not be treated as complete. Candidates can pay the application fee through NEFT. The account details for fee payment are enclosed in the notice below. They must take a print of the receipt of the fee of application form for their records and future reference.

The admit card will be sent on the candidates' registered email ID. On 28th August 2022 (tentative), candidates applying for the ADRT course can obtain their admit cards. The entrance test for the ADRT course is tentatively scheduled for 3rd September 2022. The test will be pen-paper-based and conducted from 11:00 am to 12.30 pm. There will be multiple choice questions (MCQ) of 100 marks. The test will be conducted at AIIMS Raipur. Selection to this course will be based on marks scored in the written examination only.

AIIMS has further notified that if large numbers of applications are received, nearby centers like Durg, Bhilai, and Bilaspur may be allotted. The final date of examination will be notified on admit card.

The candidates note that no entrance test will be done for PTT courses. Selection will be based on aggregate percentage marks of Physics, Chemistry and Biology obtained in the 10+2 Examination of CBSE/State Board/any other recognized Board.

After the result of the Entrance Examination, candidates belonging to Scheduled Caste/Scheduled Tribe and Other Backward Classes should submit, along with other requisite documents, an attested copy of a certificate from the prescribed authorities. Reservation for EWS shall be according to the rules of the Government of India.

The guidelines for scanning photographs and signatures are enclosed in the notice below.

Overseas Citizens of India (001) registered under Section 7A of the Citizenship Act 1955 are also eligible to appear in PG courses, and all terms and conditions for Indian Nationals will apply to the candidates. The candidate will submit proof of Registration as OCI under Section 7A of the Citizenship Act 1955 to be eligible to appear for this test.

A total of 12 seats are available for both the above courses for July 2022 session. ADRT has 2 seats, and Pre-Hospital Trauma Technician Courses have 10 seats allotted. ADRT course is for 2 years with 1 year of internship, and Pre-Hospital Trauma Technician courses are for 1 year.

Qualification required –

Advanced Diploma in Radiotherapy Technology (ADRT) – Should have passed B.Sc. with the following subjects - Physics, Chemistry, and either Biology or Mathematics) with requisite percentage of marks (50% in aggregate for General, OBC, and EWS or 45% in aggregate in case of SC/ ST Categories). Those candidates who have completed or completed the qualifying examination on or before 31.08.2022 are eligible to apply. Still, such candidates must furnish proof of passing the qualifying examination at the time of counseling failing, and their candidature will be canceled.

Pre-Hospital Trauma Technician courses – Having Passed 10+2 with Science - Physics, Chemistry, and Biology Subjects with a minimum of 55% marks in the aggregates for General candidates and 50% marks for reserved category candidates.

Those candidates who have completed the 10+2 examination on or before 31st August 2022 are eligible to apply. Still, such candidates must furnish proof of passing the qualifying examination with the requisite percentage of marks and subjects at the time of counseling, failing which their candidature will be canceled.

Age limit –

Advance Diploma in Radiotherapy Technology (ADRT) - Between 20 and 25 years as on 31st August 2022. Age relaxation of 5 years for SC/ST and 3 years for OBC candidates as per Government norms.

Pre-Hospital Trauma Technician courses - Minimum 17 years and maximum 25 years as on 31st August 2022. However, the relaxation in age will be 05 (five) years for SC and ST candidates and 3 (Three) years for OBC candidates as per Government Rules /Instructions in this regard.

Joining dates for selected candidates –

1. ADRT course – 30th September 2022

2. PTT - The information related to date of counselling and joining will be intimated later.

The selected ADRT course candidates who fail to join by 30th September 2022 and fail to submit a written request for an extension till 30th September 2022 will not be eligible for admission. They will be considered uninterested, and the seat will be offered to the next candidate on the waiting list. The last date for admission to the course will be 31st October 2022.

Course fee and stipend –

Course

Fee for the entire course

Stipend

ADRT

Rs 5856

Rs 11000 per month for 2 years

Rs 18000 per month for internship

PTT

NIL

Rs 1500 per month

The candidates must bring all the original documents with one set of photocopies at the time of counselling.

To view the notice, click on https://medicaldialogues.in/pdf_upload/62eb9e91559bffinal-advertisment-of-adrt-and-ptt-july-2022-v2-182684.pdf.

Fri, 05 Aug 2022 18:00:00 -0500 en text/html https://medicaldialogues.in/news/education/aiims-raipur-invites-applications-for-advanced-diploma-in-radiotherapy-technology-pre-hospital-trauma-technician-courses-details-97109
Killexams : LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--Aug 8, 2022--

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.

“In June, we achieved a significant milestone in LENSAR’s history, the Food and Drug Administration (“FDA”)’s clearance of our ALLY Adaptive Cataract Treatment System. Interest in the ALLY System has been high since we initiated our pre-clearance marketing efforts and continues to increase as we near the commercial placement of the first system. We are navigating supply chain challenges and expect to have approximately 10 ALLY systems placed in the U.S. in 2022.” said Nick Curtis, Chief Executive Officer of LENSAR. “Our results for the second quarter were impacted by several factors: strong U.S. procedure volumes were partially offset by softness in the rest of the world and product revenues declined as we completed placements of our last new LENSAR Laser Systems (“LLS”). We are extremely pleased with our continued progress and ability to navigate and successfully pivot around challenges outside of our company. We are proud of our ongoing accomplishments, including increasing U.S. femtosecond laser cataract procedure market share over the last few quarters, which we believe positions us well for our ALLY System launch this upcoming quarter. We view the initial launch and rollout of the ALLY System as the foundation for LENSAR’s sustainable growth and success over the long-term.”

Second Quarter 2022 Financial Results

Total revenue for the quarter ended June 30, 2022 was $8.0 million, an increase of $0.1 million, or 1%, compared to total revenue of $7.9 million for the quarter ended June 30, 2021. The increase was primarily attributable to increased procedure volume as compared to the second quarter of 2021, partially offset by a decline in revenue associated with lower LLS system sales in 2022 as we completed placement of the last new LLS systems as part of our operational transition to the ALLY System’s commercial launch in the third quarter of 2022.

For the quarter ended June 30, 2022, approximately 99% of revenue was attributable to recurring sources compared to 90% for the quarter ended June 30, 2021. The following table provides information about procedure volume:

2022

2021

Q1

38,901

28,122

Q2

33,359

30,966

Total

72,260

59,088

Selling, general and administrative expenses for the quarter ended June 30, 2022 were $7.6 million, an increase of $2.1 million, or 37%, compared to $5.5 million for the quarter ended June 30, 2021. The increase was primarily attributable to increases in sales and marketing expenses of $0.9 million, which was primarily the result of increased trade show and travel activity, and an increase in professional fees of $0.7 million.

Research and development expenses were $3.8 million and $3.0 million for the quarters ended June 30, 2022 and 2021, respectively, an increase of $0.8 million or 28%. This increase was primarily due to the continued development of ALLY.

Net loss for the quarter ended June 30, 2022 was $6.8 million, or ($0.67) per share, compared to net loss of $4.4 million, or ($0.47) per share, for the quarter ended June 30, 2021. Included within operating expenses recorded for the quarters ended June 30, 2022 and 2021 are stock-based compensation expenses recorded for the quarters ended June 30, 2022 and 2021 of $1.6 million and $1.4 million, respectively, and ALLY System inventory costs of $1.0 million and $1.1 million, respectively.

Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) for the quarter ended June 30, 2022 was ($5.9) million, compared with ($3.7) million for the quarter ended June 30, 2021. Adjusted EBITDA, which we calculate by adding back stock-based compensation expense to EBITDA, was ($4.3) million for the quarter ended June 30, 2022 and ($2.3) million for the quarter ended June 30, 2021. EBITDA and Adjusted EBITDA are non-GAAP financial measures, and a reconciliation of these measures to net loss is set forth below in this press release.

As of June 30, 2022, the Company had cash and cash equivalents of $25.2 million as compared to $31.6 million at December 31, 2021. Cash utilized in the quarter was $3.8 million, which was primarily attributable to ALLY System purchases and commercial readiness activities as well as a $1.2 million contingent consideration payment, which was contingent upon initial FDA clearance of the ALLY System. Based on its cash position and operational forecasts, the Company believes it has sufficient cash to fund operations into 2024.

Conference Call:

LENSAR management will host a conference call and live webcast to discuss the second quarter results and provide a business update today, August 8, 2022 at 8:30 a.m. ET.

To participate by telephone, please dial (888) 396-8049 (Domestic) or (416) 764-8646 (International). The conference ID number is 64265948. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. Please log in approximately 5-10 minutes prior to the call to register and to obtain and install any necessary software. The call and webcast replay will be available until August 22, 2022.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY™ Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging with a dual-pulse femtosecond laser in a compact system. ALLY is designed to transform cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s commercialization of the ALLY™ Adaptive Cataract Treatment System and expectations about the Company’s operational initiatives and business strategy, as well as the Company’s cash and operational forecasts and ability to fund ongoing operating expenses. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “target,” “mission,” “may,” “will,” “would,” “should,” “could,” “target,” “potential,” “project,” “predict,” “contemplate,” “potential,” or the negative thereof and similar words and expressions.

Each of these forward-looking statements involves risks and uncertainties. genuine results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company’s assets and business include, without limitation, its history of operating losses and ability to generate revenue; its ability to maintain, grow market acceptance of and enhance its LENSAR Laser and ALLY Systems; the impact of the COVID-19 pandemic and the Company’s ability to grow revenues; the Company’s ability to obtain any additional necessary clearances or approvals for the ALLY Adaptive Cataract Treatment System; the willingness of patients to pay the price difference for LENSAR products; its ability to grow a U.S. sales and marketing organization; its ability to meet its future capital needs; the impact of any material disruption to the supply or manufacture of ALLY Systems and its recurring revenue products; the ability of the Company to compete against competitors that have longer operating histories and more established products than the Company; the Company’s ability to address numerous international business risks; and the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, filed with the Securities and Exchange Commission (“SEC”), to be filed with the SEC, as such factors may be updated from time to time, including the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022 and in its other filings with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com. All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing LENSAR’s views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

The Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA.

EBITDA is defined as net loss before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is specifically disclosed because the Company believes that EBITDA provides meaningful supplemental information for investors regarding the performance of its business and facilitates a meaningful evaluation of genuine results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. The Company believes Adjusted EBITDA, which excludes stock-based compensation expense, provides meaningful supplemental information for investors when evaluating its results and comparing it to peer companies as stock-based compensation expense is a significant non-cash charge due to the recapitalization of the Company. It uses these non-GAAP financial measures in order to have comparable financial results to analyze changes in its underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures it use may not be directly comparable to similarly titled measures of other companies.

A reconciliation of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.

Three Months Ended
June 30,

Six Months Ended
June 30,

(Dollars in thousands)

2022

2021

2022

2021

Net loss

$

(6,759)

$

(4,362)

$

(13,433)

$

(9,544)

Less: Interest income

(39)

(13)

(48)

(31)

Add: Depreciation expense

569

342

1,110

670

Add: Amortization expense

287

309

596

622

EBITDA

(5,942)

(3,724)

(11,775)

(8,283)

Add: Stock-based compensation expense

1,637

1,430

3,244

3,750

Adjusted EBITDA

$

(4,305)

$

(2,294)

$

(8,531)

$

(4,533)

LENSAR, Inc.

STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

2021

Revenue

Product

$

5,733

$

6,056

$

12,702

$

11,214

Lease

1,415

1,140

2,814

2,251

Service

890

726

1,862

1,500

Total revenue

8,038

7,922

17,378

14,965

Cost of revenue (exclusive of amortization)

Product

1,765

2,366

4,459

4,456

Lease

484

268

958

519

Service

897

830

2,377

1,638

Total cost of revenue

3,146

3,464

7,794

6,613

Operating expenses

Selling, general and administrative expenses

7,569

5,518

13,847

11,553

Research and development expenses

3,834

3,006

8,622

5,752

Amortization of intangible assets

287

309

596

622

Operating loss

(6,798)

(4,375)

(13,481)

(9,575)

Other income

Other income, net

39

13

48

31

Net loss

$

(6,759)

$

(4,362)

$

(13,433)

$

(9,544)

Net loss per share:

Basic and diluted

$

(0.67)

$

(0.47)

$

(1.34)

$

(1.03)

Weighted-average number of shares used in calculation of net loss per share:

Basic and diluted

10,073

9,296

10,020

9,242

LENSAR, Inc.

BALANCE SHEETS

(In thousands, except per share amounts)

 

June 30, 2022

December 31, 2021

Assets

Current assets:

Cash and cash equivalents

$

25,196

$

31,637

Accounts receivable, net of allowance of $25 and $47, respectively

2,760

4,638

Notes receivable, net of allowance of $181 and $61, respectively

164

350

Inventories

5,856

6,488

Prepaid and other current assets

1,230

1,700

Total current assets

35,206

44,813

Property and equipment, net

680

756

Equipment under lease, net

7,161

6,690

Notes and other receivables, long-term, net of allowance of $1 and $2, respectively

29

121

Intangible assets, net

12,674

10,870

Other assets

2,950

3,215

Total assets

$

58,700

$

66,465

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

4,191

$

2,694

Accrued liabilities

4,372

4,604

Contingent consideration

1,200

Deferred revenue

937

904

Operating lease liabilities

521

512

Total current liabilities

11,221

8,714

Long-term operating lease liabilities

2,540

2,803

Other long-term liabilities

37

69

Total liabilities

13,798

11,586

 

Stockholders’ equity:

Preferred stock, par value $0.01 per share, 10,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued and outstanding at June 30, 2022 and December 31, 2021

Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2022 and December 31, 2021; 11,021 and 10,990 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

110

110

Additional paid-in capital

135,819

132,363

Accumulated deficit

(91,027)

(77,594)

Total stockholders’ equity

44,902

54,879

Total liabilities and stockholders’ equity

$

58,700

$

66,465

 

View source version on businesswire.com:https://www.businesswire.com/news/home/20220805005488/en/

CONTACT: Thomas R. Staab, II, CFO

ir.contact@lensar.comLee Roth / Cameron Radinovic

Burns McClellan for LENSAR

lroth@burnsmc.com/cradinovic@burnsmc.com

KEYWORD: UNITED STATES NORTH AMERICA FLORIDA

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH TECHNOLOGY SURGERY SOFTWARE OPTICAL

SOURCE: LENSAR, Inc.

Copyright Business Wire 2022.

PUB: 08/08/2022 07:00 AM/DISC: 08/08/2022 07:02 AM

http://www.businesswire.com/news/home/20220805005488/en

Sun, 07 Aug 2022 23:02:00 -0500 en text/html https://apnews.com/press-release/BusinessWire/technology-health-cataracts-medical-69cc8dfd6a9b48e3a4a522ec5e0c2fdf
Killexams : NEET UG 2022: NTA to Release NEET Answer Key, Result Soon at neet.nta.nic.in| Check Marking Scheme Here

NEET UG 2022 Latest Update: The National Testing Agency (NTA) will release the answer key for National Eligibility Cum Entrance Test-Undergraduate (NEET-UG) 2022 anytime soon. This time, more than 18 lakh NEET aspirants have appeared for the single largest medical entrance examination held on July 17, 2022. As per several news reports, NEET UG 2022 Answer Key is likely to be released this week. Once issued, candidates can obtain the NEET UG Answer Key 2022 through the official website neet.nta.nic.in. However, it is to be  noted that NTA has not released any specific date/time for the declaration of the result or answer key.Also Read - JEE Main 2022 Session 2 Final Answer Key Released For Paper 1; Here's How to obtain at jeemain.nta.nic.in

The Agency will also release the Candidate’s response sheet, NEET UG Result along with NEET UG 2022 Answer Key on its website. Below are the marking scheme and the steps to obtain the NEET UG Answer Key 2022. Also Read - JEE Advanced 2022 Registration Begins at jeeadv.ac.in; Steps to Fill Application Form Here

How to obtain NEET UG 2022 Answer Key?

In order to obtain the Answer Key, a registered candidate can follow the steps given below:

  1. Visit the official website of NEET at neet.nta.nic.in.
  2. Click on the link that reads, “NEET UG 2022 Answer Key” given at the bottom of the homepage.
  3. Enter the login credentials such as NEET Application No and Date of Birth/password and click on submit option.
  4. Your NEET UG 2022 Answer will be displayed on the screen.
  5. Download the answer key and take a printout of it for future reference.

NEET UG Answer Key 2022: Check Marking Scheme HERE

For Section A (MCQs): To answer a question, the candidates need to choose one option corresponding to the correct answer or the most appropriate answer.

  • Correct answer or the most appropriate answer: Four marks (+4)
  • Any incorrect option marked will be given minus one mark (-1).
  • Unanswered/Marked for Review will be given no mark (0).
  • If more than one option is found to be correct then Four marks (+4) will be awarded to only those who have marked any of the correct options.
  • If all options are found to be correct then Four marks (+4) will be awarded to all those who have attempted the question.
  • If none of the options is found correct or a Question is found to be wrong or a Question is dropped then all candidates who have appeared will be given four marks (+4) irrespective of the fact whether the question has been attempted or not attempted by the candidate.

For Section B (MCQs): As per the Information Bulletin of NEET UG-2022, Candidates need to attempt any 10 Questions out of 15 Questions given. There will also be negative marking for Section B.

  • Correct Answer: Four marks (+4)
  • Incorrect Answer: Minus one mark (-1)
  • Unanswered/Marked for Review: No mark (0).
  • If more than one option is found to be correct then Four marks (+4) will be awarded to only those who have marked any of the correct options.
  • If all options are found to be correct then Four marks (+4) will be awarded to all those who have attempted the question.
  • If a question is found to be incorrect or the Question is dropped then Four marks (+4) will be awarded to all those who have attempted the question. The reason could be due to human error or technical error.
  • Candidates are advised to do the calculations with the constants given (if any) in the questions.

NEET UG 2022 — Highlights

  • NEET 2022 test Date: July 17, 2022
  • NEET Official Website(s): www.nta.ac.in , https://neet.nta.nic.in/
  • Display of Recorded Responses and Answer Keys: To be announced later on the website.
  • Declaration of NEET UG 2022 Result on NTA website To be announced later on the website.

For more details, candidates are advised to go through the official information bulletin of NEET UG 2022.

Sat, 06 Aug 2022 21:18:00 -0500 en text/html https://www.india.com/education/neet-ug-2022-answer-key-latest-news-nta-to-release-answer-key-neet-result-soon-check-marking-scheme-at-neet-nta-nic-in-in-nta-neet-2022-5558583/
Killexams : Medical Supplies Market worth $163.5 billion by 2027 – Exclusive Report by MarketsandMarkets™

MarketsandMarkets Research Pvt. Ltd.

Chicago, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medical Supplies Market is projected to grow from USD 138.4 billion in 2022 to USD 163.5 billion by 2027, at a CAGR of 3.4% from 2022 to 2027 according to a new report by MarketsandMarkets™. The Growth in this market can be attributed to the expanding geriatric population, increasing research investments, high volume of surgical procedures, and the high prevalence of chronic diseases.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64344238

Browse in-depth TOC on “Medical Supplies Market
174 – Tables
39 – Figures
281 – Pages

In 2021, intubation & ventilation supplies accounted for the largest share of the medical supplies market, by type.

By type, the medical supplies market is segmented into diagnostic supplies, dialysis consumables, wound care consumables, radiology consumables, disinfectants, infusion & injectable supplies, intubation & ventilation supplies, personal protective equipment, sterilization consumables, catheters, sleep apnea consumables, and other medical supplies. In. The intubation & ventilation supplies segment held the highest share which is attributed to its massive demand amid the outbreak of novel coronavirus. The overwhelming influx of the COVID-19 patients placed a huge demand for the intubation & ventilation supplies which fuelled the share of the market.

By other application accounted for the largest market share in 2021.

Based on the application, the medical supplies market is segmented into urology, wound care, radiology, respiratory, infection control, cardiology, IVD, and other applications. The other application segment held the largest share. The other application areas include the dentistry, neurology, gastroenterology, orthopedics, and waste management applications. The market share of the segment is driven by the high numbers of surgeries, and increasing prevalence of neurological disorders, dental diseases, GI disorders, and others.

By end user, hospitals accounted for the largest market share in 2021.

Based on end user, the market is segmented into hospitals, clinics/physician offices, and other end users. In 2021, the hospitals segment accounted for the largest share of the market. This can be attributed to the increasing healthcare investments, and advanced infrastructure.

Request trial Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64344238

North America was the largest regional market for medical supplies market in 2021.

The medical supplies market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Rest of the World. North America held the largest share of the market in 2021, followed by Europe. The largest market share of North America is driven by the high incidence of strong presence of industry players, high prevalence of chronic and infectious diseases, and advanced healthcare infrastructure in the region.

Some of the major players operating in the medical supplies market are Medtronic plc (Ireland), Cardinal Health (US), BD (US), Johnson & Johnson, Inc. (US), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US), Thermo Fisher Scientific, Inc. (US), Baxter (US), 3M (US), Smith & Nephew (Ireland), Convatec Inc. (UK), Abbott (US), Cook Medical (US), Merit Medical Systems (US), Stryker (US), Terumo Corporation (Japan), Teleflex Incorporated (US), Fresenius Medical Care AG & Co. KGaA (Germany), Coloplast Group (Denmark), Hamilton Medical (Switzerland), ACell, Inc. (US), Invacare Corporation (US), Medline Industries, LP. (US), DeRoyal Industries, Inc. (US), Shenzhen MedRena Biotech Co., Ltd. (China), Kerecis (US) and Whiteley (Australia).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64344238

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Related Reports:

Infection Control Market by Product [Sterilization (Steam, Hydrogen Peroxide, EtO), Disinfection (Wipes, Liquids, Disinfectors), Services, E-beam, Face Masks], End User (Hospitals, Pharmaceutical Companies) (2022 - 2026)

CONTACT: About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com
Fri, 05 Aug 2022 02:30:00 -0500 en-NZ text/html https://nz.finance.yahoo.com/news/medical-supplies-market-worth-163-143000186.html
Killexams : From NEET UG Answer Key to JEE Advanced 2022 Registration; Check Important Education Events For August No result found, try new keyword!The month of August would be buzzing with a lot of activities related to academics, entrance exams, and results. Right from JEE Advanced test to CAT 2022 registration process, it’s a ful ... Mon, 01 Aug 2022 08:22:28 -0500 en-in text/html https://www.msn.com/en-in/news/other/from-neet-ug-answer-key-to-jee-advanced-2022-registration-check-important-education-events-for-august/ar-AA10bIEL Killexams : Medical Device Accessories Market 2022, Growth, Business Opportunities, Revenue, Gross Margin and Forecast 2030

The MarketWatch News Department was not involved in the creation of this content.

Aug 01, 2022 (Alliance News via COMTEX) -- Report Ocean published the latest research report on the Medical Device Accessories market. In order to comprehend a market holistically, a variety of factors must be evaluated, including demographics, business cycles, and microeconomic requirements that pertain precisely to the market under study. In addition, the Medical Device Accessories market study demonstrates a detailed examination of the business state, which represents creative ways for company growth, financial factors such as production value, key regions, and growth rate.

The cardiovascular device accounted for the largest market share in 2016 and is expected to grow at a CAGR of 7.24%.

Introduction
The global medical device and accessories market is driven by an increasing prevalence of chronic diseases and the growing demand for technologically advanced medical devices. Additionally, improvement of surgical outcomes and rising aging population also influence the market growth.
On the basis of the types of devices, the global medical device and accessories market is segmented into cardiovascular application, coronary pressure monitors, catheters, therapeutic medical guide, dental implant, cochlear implant, the global nerve stimulator market, the global diabetes monitors market, and the global suture needles market. Furthermore, the cardiovascular application segment is sub-segmented into cardiac monitors, cardiac pacemakers, cardiac defibrillators, and others.

Request To obtain Free trial of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=19202

The coronary pressure monitor segment is sub-segmented into sphygmomanometer, automated blood pressure monitor, BP transducers, ambulatory blood pressure monitor, and instruments and accessories. The catheter segment is further sub-segmented into cardiovascular catheters, specialty catheters, intravenous catheters, urinary catheters, neurological catheters. The therapeutic medical guidewire segment is sub-segmented into solid guidewire and wrapped guidewire. The nerve stimulator market is sub-segmented into deep brain stimulator, vagus nerve stimulator, and spinal cord stimulator.

Key Players
The leading market players in the global medical device and accessories market include Boston Scientific Corporation, Medtronic, Johnson & Johnson Services, Inc., Stryker Corporation, Koninklijke Philips N.V., General Electric Company, Siemens AG, and Danaher Corporation.

Study Objectives of the Medical Device & Accessories Market
> To provide insights into factors influencing and affecting the market growth
> To provide historical and forecast revenues of market segments and sub-segments with respect to regional- and country-level markets
> To provide historical and forecast revenue of market segments based on type, product, application, end-user, and its sub-segments.
> To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape of the market.

SPECIAL OFFER (Avail an Up-to 30% discount on this report:-https://reportocean.com/industry-verticals/sample-request?report_id=19202

Target Audience
> Medical Device Companies
> Research and Development (R&D) Companies
> Government Research Institute
> Academic Institutes and Universities
> Medical Research Laboratories
> Market Research and Consulting Service Providers
> Potential Investors

Key Finding
> The global medical device and accessories market accounted for USD 79,879 million in 2016.
> The coronary pressure monitors segment is the fastest growing segment, which is projected to grow at a CAGR of 6.65% during the forecast period, 2017 to 2023.
> The Americas region captured the largest market globally and is expected to be USD 47,887 million by 2023.
> Asia Pacific is the fastest growing region across the globe and is expected to grow at a CAGR of 7.12% during the forecast period.

Access full Report Description, TOC, Table of Figure, Chart, etc. @:-https://reportocean.com/industry-verticals/sample-request?report_id=19202

Country-Level Analysis
> Americas
> North America
o U.S.
o Canada
> Latin America
> Europe
> Western Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Western Europe
> Eastern Europe
> Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia Pacific
> Middle East & Africa
o Middle East
o Africa

Table of Content

Market Overview
Market Dynamics
Associated Industry Assessment
Market Competitive Landscape
Analysis of Leading Companies
Market Analysis and Forecast, By Product Types
Market Analysis and Forecast, By Applications
Market Analysis and Forecast, By Regions
Conclusions and Recommendations
Appendix

Access Full Report, here:- https://reportocean.com/industry-verticals/sample-request?report_id=19202

About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today's competitive environment. Report Ocean is a 'one-stop solution' for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:
Report Ocean:
Email:sales@reportocean.com
Address
: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 - UNITED STATES Tel: +1 888 212 3539 (US - TOLL FREE)
Website:https://www.reportocean.com/

COMTEX_411350028/2796/2022-08-01T09:26:02

The MarketWatch News Department was not involved in the creation of this content.

Mon, 01 Aug 2022 01:26:00 -0500 en-US text/html https://www.marketwatch.com/press-release/medical-device-accessories-market-2022-growth-business-opportunities-revenue-gross-margin-and-forecast-2030-2022-08-01
Killexams : Limitless Guided Visualizations App Partners with International Regenerative Medicine Provider BioReset Medical®️ to Strengthen Patient Outcomes

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

SAN JOSE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Limitless Guided Visualizations ™ (“Limitless”) today announced its first partnership with BioReset Medical®️, an international network of regenerative medicine clinics, to provide a first-of-its-kind approach to ketamine therapy. The audio journeys in the Limitless Guided Visualizations app help patients navigate their mindset during treatments and give providers a way to support their patients’ integration between treatments.

“Limitless is an invaluable addition to our multi-modality treatment approach. We believe that empowering patients to actively participate in their mental health journey is an important part of the healing process. Limitless helps our patients to prepare for their ketamine therapy, navigate their mindset during sessions and provides a safe container for them to continue to do the work in-between treatments,” said Matt Cook, MD, founder of BioReset Medical®️.

Limitless teaches the Metacognitive Healing Methodology™, which evokes awareness of one’s thought processes and helps them understand the patterns behind their thoughts, using a variety of techniques proven to alter states of consciousness. By changing the relationship patients have with themselves and their perspectives on life, their sources of trauma can be revealed and transformed.

The BioReset Medical®️ ‘Stress Reset’ treatment packages integrate advanced medical techniques (including ketamine and stellate ganglion blocks) with added cognitive support through the Limitless app. These packages are designed to support patients with: chronic illness, depression, anxiety, PTSD, trauma, mood disorders, emotional distress, chronic pain, and repetitive thoughts.

Benefits seen by patients may include:

  • Establishing a mindset for healthy internal dialogue
  • Improving the body’s ability to heal itself by calming fight/flight/freeze/fawn reactions
  • Becoming aware of unproductive/unhelpful thought patterns
  • Creating new neural pathways that help the brain adapt, learn and create new memories

“The interconnectedness of mental health and physical health is often overlooked in current treatment models. We are thrilled to partner with BioReset Medical®️ visionaries who provide world-class regenerative medicine to their patients. Incorporating Metacognitive Healing™ in their treatment approach demonstrates their well-earned title of ’thought leaders,” said Cali, the founder of Limitless Guided Visualizations and creator of the Metacognitive Healing Methodology™.

Every BioReset patient who medically qualifies for the Stress Reset package receives a year of premium access to the Limitless Guided Visualizations mobile app to support their healing journey. The packages include an initial series of eight ketamine therapy sessions, typically completed in 4-8 weeks, with the potential for booster treatments as needed.

During treatment, patients are set up in a comfortable recliner and are invited to listen to music or select a 90+ minute journey on the Limitless Guided Visualizations™ app. Then, they put on an eye mask and ‘float’ through their infusion over the course of an hour or so. In-app themes for these profound healing experiences include safety, wellness, love, resilience, presence, and flow. Patients are also encouraged to utilize the app in-between ketamine therapy sessions to develop skills in achieving personal clarity through 10+ minute Mindset Microdoses, which are brief foundational lessons of the techniques used in the longer journeys.

Limitless’s partnership model is adaptable and easy to roll out. “Limitless was designed to Strengthen treatment efficacy in many different environments: ketamine clinics, float spas, wellness centers, IV clinics, functional medicine clinics and beyond,” said Cali.

Limitless Guided Visualizations™ amplify psychedelic and medicine-based treatments but are not exclusive to in-clinic experiences. This lifestyle and wellness app has distilled decades of clinical expertise into an accessible model to help people access naturally altered states with or without medicine. Limitless is free to obtain in the App Store and on Google Play. The premium access content that BioReset’s patients receive includes an extended menu of guided visualizations, which can also be purchased directly through the app.

About Limitless

Limitless Guided Visualizations ™ is a lifestyle and wellness app that empowers people to become the champion of their own personal health journeys. The Metacognitive Healing Methodology™ that Limitless teaches, leverages decades of clinical experience to help people access naturally altered states. In-app guided visualizations support a shift in consciousness through a whole body-being experience that draws on lessons from both psychedelic medicine and established health and wellness solutions. Cali, the founder of Limitless, developed the Metacognitive Healing Methodology™ in 2001 and began testing in a clinical setting in 2018.

About BioReset Medical

BioReset Medical ®️ is an expanding network of visionary clinics where practitioners aim to be as non-invasive as possible, believing that the body performs a natural function of healing when supported by real care and the best technology. Profound and dynamic practitioner-patient relationships support the entire healing process via their concierge regenerative medicine model. Every treatment plan is personalized to each patient’s unique health needs and is designed to address issues at their root rather than treating individual symptoms as they arise.

MEDIA CONTACT:
Trevor Maniscalo
NisonCo PR
trevor@NisonCo.com
(630) 841-1017

Tue, 02 Aug 2022 00:27:00 -0500 en text/html https://apnews.com/press-release/globe-newswire/technology-health-14d781ba0c857b8e05fc9314c3900043
Killexams : Florida Board of Medicine targets treatments for transgender youths

Amid an outcry from the LGBTQ community and harsh criticism from a host of physicians and health-care professionals, the Florida Board of Medicine on Friday advanced a plan that would ban doctors from providing treatments such as puberty blockers and hormone therapy to transgender people under age 18.

Friday’s decision came after the Florida Department of Health last month filed a petition asking the medical board to initiate a rule-making process on the contentious issue. The Board of Medicine also moved forward as the state Agency for Health Care Administration plans to prevent the Medicaid program from covering such treatments for gender dysphoria for adolescents and adults.

>>> STREAM ACTION NEWS JAX LIVE <<<

[DOWNLOAD: Free Action News Jax app for alerts as news breaks]

As his political presence on the national stage continues to skyrocket, Gov. Ron DeSantis is among Republican leaders throughout the country targeting transgender treatments for youths. The governor, who is seeking re-election in November, contends that children are prematurely being allowed to pursue treatments that can have harmful lasting effects.

But many medical professionals — including numerous medical societies — are blasting the DeSantis administration’s moves, saying the state’s assertions are contrary to established standards.

People on both sides of the issue crowded into Friday’s Board of Medicine meeting in Broward County, with supporters of the Department of Health proposal wearing “Let Kids Be Kids” decals. Opponents held a rally before the meeting and pleaded with the board to reject the petition.

Addressing the board, Department of Health Secretary Joseph Ladapo acknowledged the “strong feelings about the issue” in the room.

But Ladapo, who serves as the state’s surgeon general, argued that current standards of care are a “substantial departure” from “the level of evidence and data surrounding this issue.”

“It is very clear that … the effectiveness is completely uncertain,” Ladapo, who said his views on the course had “evolved,” argued. “I mean, maybe it is effective, but the scientific studies that have been published today do not support that. … Could that change in the future? It’s possible. I think it’s very unlikely considering what I’ve reviewed, but it’s possible.”

Quentin Van Meter, a pediatric endocrinologist who served as an expert for the state on the issue, warned the board that an increasing number of children are seeking puberty blockers or other medical interventions.

Read: Council considers bill allowing ‘backyard cottages’ to help affordable housing crisis

“This is what we are dealing with. We’re dealing with a monumental epidemic of increasing proportions,” said Van Meter, who is an outspoken critic of transgender treatment for young people. “This is a giant experiment on United States children.”

Van Meter also said Sweden, Finland and the United Kingdom have halted treatment for transgender youths because “they found that there was far more harm than any benefit in allowing these children to receive any kind of medical intervention.” According to Van Meter, roughly 127,000 children throughout the U.S. are receiving gender-affirming treatment.

But Michael Haller, a professor and chief of pediatric endocrinology at the University of Florida, disputed Van Meter’s comments, saying fewer children are receiving gender-affirming hormones or other therapy than the public has been led to believe and that the numbers aren’t growing.

Haller and other doctors also have argued that standards of care for trans youths were developed by professional medical societies after years of vigorous scientific debate.

Questioning Haller, board Chairman David Diamond noted that other countries have changed their approaches to treatment of gender dysphoria, which the federal government defines clinically as “significant distress that a person may feel when sex or gender assigned at birth is not the same as their identity.”

“Do you have any sense what the scientific underpinning may be, why they have modified their opinions, or is it your contention it was not a scientific decision but rather based upon other factors?” Diamond asked.

“I think it’s impossible to fully separate the political decision-making from the science,” Haller said.

Diamond, an oncologist, pointed to breast-cancer treatments adopted in the 1990s that later were discovered to be harmful.

“The bottom line is, just because you think something works, does not mean it works,” the board chairman said. “The point is … we must continuously assess what we’re doing and have the capacity to say maybe what we’re doing is wrong. Maybe our beliefs are wrong. Maybe we can listen to the other person on the other side or accept the newer data and potentially make our position a little bit better, a little more refined, to better seek the truth.”

Diamond asked Haller and his UF colleague, Kristin Dayton, if they believed the board should adopt guidelines or rules for gender dysphoria.

Read: Lawsuits allege local hospital knew of and ignored surgeon’s impairments and botched surgeries

Dayton, a pediatric endocrinologist who specializes in gender dysphoria, said such a plan would be “redundant” because standards of care already exist. But Haller indicated he didn’t trust the state to advance its own plan.

“If the redundancy were such that it was in line with the general practices and data, then I think it would be adequate. But it’s clear that is not the intent of the state,” Heller said. “They have provided you with a recommendation for a rule that is contrary to what almost all reasonable providers of gender-affirming care and gender care in general would say is the standard of care.”

If guidelines are finalized, Florida would be the only state in the country where a medical board has barred transgender treatments for adolescents, according to Yale School of Medicine professor Meredithe McNamara.

A handful of other states have passed laws blocking the treatment, but McNamara, who specializes in adolescent medicine, told The News Service of Florida this week that she’s “never heard of” a state medical board prohibiting such care.

“Standards of health care don’t come from states, don’t come from governments. They come from clinical research that gets reviewed and vetted and discussed in relevant groups of experts and published and spread widely and adopted by people everywhere,” she said.

Many of Friday’s attendees urged the board to accept the health department’s petition, but Kaleb Hobson-Garcia said he made the seven-hour drive from Tallahassee to share his experiences with the panel.

“I wasn’t always the 20-year-old man you see standing in front of you. … I used to be an 11-year-old kid who had just changed his name to Kaleb,” he said.

Read: Jacksonville father and son plead guilty to defrauding the IRS of $5.6 million

Hobson-Garcia, 20, said he and his parents consulted with a doctor for a year before he began medical treatment. He said began taking puberty blockers at age 12, hormone suppressants at age 13 and underwent “top surgery” at age 14. Despite his experiences, Hobson-Garcia said he agrees with current guidelines that recommend a minimum age of 16 for “top” surgery and 18 for “bottom” surgery, or penis removal.

“The medical treatment I received as a minor was integral to me climbing out of my depression and becoming the happy and healthy person I am today,” Hobson-Garcia said. “My identity is not an epidemic. We cannot stand to lose progress towards a happier, healthier future for all Floridians.”

Kevin Cairns, an interventional pain specialist who serves as the board’s vice chairman, was the sole member of the board to vote against granting the Department of Health’s petition to begin the rule-making process.

Ernie Sauve was among the people who asked the board to move forward with the plan. As someone who speaks Spanish fluently, Sauve said he “could identify” as a Spanish person, but that does not make him Spanish.

“Back in my day, women were women. Let children be children. … Let’s get back to reason, to common sense, and to truth,” he said.

[SIGN UP: Action News Jax Daily Headlines Newsletter]

Click here to obtain the free Action News Jax news and weather apps, click here to obtain the Action News Jax Now app for your smart TV and click here to stream Action News Jax live.

Fri, 05 Aug 2022 12:07:00 -0500 en-US text/html https://news.yahoo.com/florida-board-medicine-targets-treatments-000734764.html
ACLS exam dump and training guide direct download
Training Exams List